Poolbeg Pharma PLC has announced the grant of its first national patent covering the POLB-001 programme, which addresses cytokine release syndrome induced by cancer immunotherapy. The development represents a significant
Poolbeg Pharma PLC has announced the grant of its first national patent covering the POLB-001 programme, which addresses cytokine release syndrome induced by cancer immunotherapy. The development represents a significant






